Tiziana Life Sciences Announces Purchase of Shares by Chairman
1. Executive Chairman purchased 25,000 shares at $1.60, holding 36.28%. 2. Foralumab shows potential in treating neuroinflammatory diseases with favorable safety. 3. Current trials for foralumab include patients with non-active MS are ongoing. 4. Tiziana's nasal drug delivery method aims for enhanced efficacy and safety. 5. Pending patents may broaden Tiziana's immunotherapy applications.